Editas Medicine, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.editasmedicine.com

Moat Score

Market Cap $186.50M
PE -1
Debt $NaN
Cash $99.71M
EV $NaN
FCF -$191.36M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$210.57M
EBIT	-$228.52M
ROE	-120%
ROA	-70%
FCF	-$191.36M
Equity	$175.63M
Growth Stability	1
PE	-0.89
PB	1.06
P/FCF	-0.97
P/S	3.02
Price/Cash	0.53
Net Margins	-11K%
Op. Margins	-370%
Sales Growth YoY	-99%
Sales Growth QoQ	-88%
Sales CAGR	10%
Equity CAGR	10%
Earnings Growth YoY	38%

Earnings Growth QoQ	-8%
Sales CAGR 5Y	3%
Equity CAGR 5Y	-9%
Earnings CAGR 3Y	52%
Sales CAGR 3Y	52%
Equity CAGR 3Y	-28%
Market Cap	$186.50M
Revenue	$61.76M
Assets	$327.57M
Cash	$99.71M
Shares Outstanding	82.25M
Moat Score	0%
Working Capital	198.79M
Current Ratio	3.75
Shares Growth 3y	8%
Equity Growth QoQ	-24%
Equity Growth YoY	-51%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology.

SEC Filings

Direct access to Editas Medicine, Inc. (EDIT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Editas Medicine, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Editas Medicine, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Editas Medicine, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Editas Medicine, Inc..

Years

Calculation mode

= -$1.9B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$191M	-$191M	-$191M	-$191M	-$191M	-$191M	-$191M	-$191M	-$191M	-$191M	-$191M	-$1.9B
DCF		-$174M	-$158M	-$144M	-$131M	-$119M	-$108M	-$98M	-$89M	-$81M	-$74M	-$738M
Value	-$1.9B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-2K%	-876%	-344%	-651%	-128%	-754%	-1K%	-196%	-11K%
ROA	-	-24%	-42%	-32%	-27%	-28%	-24%	-29%	-44%	-34%	-70%
ROE	-	88%	-72%	-58%	-47%	-51%	-29%	-35%	-61%	-44%	-120%

Bad Net Margins (-11.21K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	127%	133%	-36%	342%	-72%	-23%	296%	3%
Earnings YoY growth	-	424%	33%	24%	-9%	22%	-13%	66%	15%	-30%	-
Equity YoY growth	-	444%	-262%	55%	13%	11%	50%	41%	-35%	-3%	-9%
FCF YoY growth	-	-31%	682%	-79%	340%	-7%	299%	-8%	6%	-25%	-